Millennium Pharmaceuticals will focus on expanding its existing drug pipeline instead of aggressively pursuing new drug acquisitions, at the request of shareholders, CEO Deborah Dunsire said Thursday. Millennium is working to pitch its experimental atherosclerosis antibody to potential partners, as well as expanding sales of its multiple myeloma treatment Velcade.

Full Story:

Related Summaries